The objective of the study was to assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/feature-article/hydroxychloroquine-patients-mainly-mild-moderate-coronavirus-disease-2019-open-label
[2] http://admin.indiaenvironmentportal.org.in/category/author/wei-tang
[3] http://admin.indiaenvironmentportal.org.in/category/author/zhujun-cao
[4] http://admin.indiaenvironmentportal.org.in/category/author/mingfeng-han-et-al
[5] http://admin.indiaenvironmentportal.org.in/category/journal/bmj
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/coronavirus
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/malaria
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/medical-research
[10] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health-effects
[11] http://admin.indiaenvironmentportal.org.in/category/thesaurus/china
